In the ongoing clinical study, the first treatment with the new generation of SpectraCure's system Q-PRO® with integrated image processing technology was performed in November. The treatment was performed at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. The procedure went according to plan, and the system met the highly set expectations.
Dr. James A. Eastham is the investigator at MSKCC in New York and the first Doctor to use the new generation of SpectraCure’s Q-PRO® treatment system in the clinical study. Dr. Eastham is a surgeon who specializes in nerve-sparing prostatectomy for the treatment of prostate cancer and salvage radical prostatectomy in patients with prostate cancer in whom radiation therapy has failed.
The company has received positive feedback regarding the usability of SpectraCure’s Q-PRO® system after the first treatment at MSKCC.
”The SpectraCure system is user-friendly,” said Doctor James A. Eastham. “Anyone familiar with transperineal prostate biopsy or prostate brachytherapy will be comfortable with the device. Overall, technically very simple and fortunately well-tolerated by the patient. Looking forward to using the SpectraCure system soon.”
“It is very encouraging that the new system was well-received by Dr. Eastham and his team at MSKCC, and equally encouraging that the first patient treated with the system is well,” says Johannes Swartling, CTO at SpectraCure. “The main goal of the clinical trial is, of course, to evaluate the medical aspects of the treatment, but evaluating the usability of the system is also required, and this is an important step in this work.”
SpectraCure is developing a treatment system for the elimination of internal solid cancer tumors. We are initially focusing on recurrent prostate cancer, hoping to treat other cancers such as primary prostate cancer, breast cancer, pancreatic cancer, and head and neck cancer in the future. The approach is based on a proprietary and patented treatment system, Q-PRO®, consisting of a hardware device and a laser unit, which performs PDT treatment and treats the prostate itself, combined with a software device, the patented IDOSE® dose planning platform. The method allows the laser light dose to be controlled so that the tumour is exposed to an optimal dose to achieve sufficient treatment effect. The treatment system has the potential to make interstitial PDT treatment accurate, precise, safe for every patient. The goal is that in addition to being tumor free, the patient will be able to maintain their quality of life, with limited side effects. We are conducting clinical trials as an important part of the continued development of the company's treatment system.
The company is listed in the Premier segment of the Nasdaq First North Growth Market with G&W Fondkommission as Certified Adviser, and trades under the short name SPEC.